BeOne Medicines (BSP:B1ME34) Cyclically Adjusted FCF per Share: R$-2.20 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1ME34 BeOne Medicines Ltd BSP:B1ME34
77 GF Score
Price R$64.68
GF Value R$72.75
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted FCF per Share?

BeOne Medicines BSP:B1ME34 77 Cyclically Adjusted FCF per Share is R$-2.20 as of Mar. 2026. GuruFocus rates BSP:B1ME34 with a GF Score™ of 77/100 and a GF Value™ of R$72.75. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BeOne Medicines's adjusted free cash flow per share for the three months ended in Mar. 2026 was R$0.290. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$-2.20 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-29), BeOne Medicines's current stock price is R$64.68. BeOne Medicines's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was R$-2.20. BeOne Medicines's Cyclically Adjusted Price-to-FCF of today is .


BeOne Medicines  (BSP:B1ME34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BeOne Medicines Cyclically Adjusted FCF per Share Related Terms


BeOne Medicines Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted FCF per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.80 -2.47

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.64 -2.54 -2.33 -2.47 -2.20

BSP:B1ME34 vs ALNY, RVMD, RPRX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted Price-to-FCF falls into.


BSP:B1ME34
77GF Score
BeOne Medicines Ltd BSP:B1ME34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.29/108.0600*108.0600
=0.290

Current CPI (Mar. 2026) = 108.0600.

BeOne Medicines Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.103 100.088 -0.111
201609 -0.122 99.604 -0.132
201612 -0.129 99.380 -0.140
201703 -0.136 100.040 -0.147
201706 -0.217 100.285 -0.234
201709 -0.033 100.254 -0.036
201712 0.217 100.213 0.234
201803 -0.316 100.836 -0.339
201806 -0.359 101.435 -0.382
201809 -0.460 101.246 -0.491
201812 -0.725 100.906 -0.776
201903 -0.574 101.571 -0.611
201906 -0.226 102.044 -0.239
201909 -0.811 101.396 -0.864
201912 -0.819 101.063 -0.876
202003 -1.027 101.048 -1.098
202006 -0.789 100.743 -0.846
202009 -1.030 100.585 -1.107
202012 -0.876 100.241 -0.944
202103 0.173 100.800 0.185
202106 -1.005 101.352 -1.072
202109 -1.281 101.533 -1.363
202112 -1.585 101.776 -1.683
202203 -0.693 103.205 -0.726
202206 -0.845 104.783 -0.871
202209 -1.400 104.835 -1.443
202212 -0.987 104.666 -1.019
202303 -1.379 106.245 -1.403
202306 -0.771 106.576 -0.782
202309 -0.481 106.570 -0.488
202312 -0.732 106.461 -0.743
202403 -0.958 107.355 -0.964
202406 -0.423 107.991 -0.423
202409 0.114 107.468 0.115
202412 -0.039 107.128 -0.039
202503 -0.150 107.722 -0.150
202506 0.394 108.075 0.394
202509 0.663 107.710 0.665
202512 0.717 107.200 0.723
202603 0.290 108.060 0.290

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$-2.20 mean?
BeOne Medicines (BSP:B1ME34) has a Cyclically Adjusted FCF per Share of R$-2.20 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted FCF per Share too high?
BeOne Medicines' current Cyclically Adjusted FCF per Share is R$-2.20. Overall, BeOne Medicines has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted FCF per Share compare to ALNY and RVMD?
BeOne Medicines' Cyclically Adjusted FCF per Share of R$-2.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted FCF per Share is R$-2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (BSP:B1ME34) has a current Cyclically Adjusted FCF per Share of R$-2.20. The stock's GF Value™ is R$72.75, compared to a current price of R$64.68 — trading 11.1% below its estimated fair value. The current Cyclically Adjusted FCF per Share is R$-2.20. BeOne Medicines' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BeOne Medicines (BSP:B1ME34), the current Cyclically Adjusted FCF per Share is R$-2.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (BSP:B1ME34) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of R$64.68 is trading 11.1% below its estimated GF Value™ of R$72.75.

Key valuation signals for BSP:B1ME34:

  • Cyclically Adjusted FCF per Share: R$-2.20
  • GF Value™: R$72.75 vs. price of R$64.68 (11.1% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the BSP:B1ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score

Get the complete analysis for BSP:B1ME34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$64.68
Price
R$72.75
GF Value